drugset / Trial / NCT06415669
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.
Timeline
- Start
- 2024-05-19
- Primary completion
- 2026-05-19
- Completion
- 2027-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 20 mg/kg | — |
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 250 mg | — |